May 29, 2024
TOPLINE: The addition of bupropion/naltrexone to glucagon-like peptide 1 (GLP-1) receptor agonists leads to a further 4%-5% total body weight loss (TBWL) in patients with obesity, […]
May 28, 2024
BERLIN — What is the best way to help patients with diabetes, heart problems, and obesity lose weight and improve their outcomes? Is it exercise or […]
May 28, 2024
(Reuters) – As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be […]
May 27, 2024
TOPLINE: In women with gestational diabetes (GD), continuous glucose monitoring (CGM) shows elevated glycemic metrics earlier in pregnancy compared with the standard oral glucose tolerance test […]
May 25, 2024
In a 7 to 4 vote, an advisory panel to the US Food and Drug Administration (FDA) determined that the potential benefits of the investigational once-weekly […]
May 24, 2024
NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken […]
May 23, 2024
DENVER — Postmenopausal women who receive hormone therapy show significantly greater weight loss when treated with the glucagon-like peptide 1 (GLP-1) receptor agonist drug semaglutide than […]
May 23, 2024
Cortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules (SPNs) with two distinct layers — one tumorigenic and one tumor suppressive — reported Japanese […]
May 22, 2024
TOPLINE: An early serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) has been validated as a safe and useful screening test with 100% specificity […]